The estimated Net Worth of Allison Frisbee is at least $209 Tisíc dollars as of 21 February 2024. Allison Frisbee owns over 12,105 units of Kronos Bio stock worth over $196,309 and over the last few years Allison sold KRON stock worth over $12,710.
Allison has made over 1 trades of the Kronos Bio stock since 2024, according to the Form 4 filled with the SEC. Most recently Allison sold 12,105 units of KRON stock worth $12,710 on 21 February 2024.
The largest trade Allison's ever made was selling 12,105 units of Kronos Bio stock on 21 February 2024 worth over $12,710. On average, Allison trades about 12,105 units every 0 days since 2024. As of 21 February 2024 Allison still owns at least 204,510 units of Kronos Bio stock.
You can see the complete history of Allison Frisbee stock trades at the bottom of the page.
Allison's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Over the last 4 years, insiders at Kronos Bio have traded over $6,434,800 worth of Kronos Bio stock and bought 7,151,111 units worth $30,320,233 . The most active insiders traders include John C Martin, Norbert W Bischofberger a Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of $178,391. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth $732,466.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Kronos Bio executives and other stock owners filed with the SEC include: